Filing Flows › Lenz Therapeutics (LENZ) › Q1 2026
Lenz Therapeutics (LENZ) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 11, 2026
Lenz Therapeutics (LENZ) reported revenue of $1.9M for the first quarter 2026 (Q1 2026) and +20% from the quarter before.
Lenz Therapeutics, Q1 2026: revenue $1.9M, net loss $41.5M, operating cash flow −$33.6M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.9M | +20% | — |
| Operating profit | −$44.1M | — | — |
| Net earnings | −$41.5M | — | — |
| Operating cash flow | −$33.6M | — | — |
What changed
Revenue was $1.9M in Q1 2026, up 20% from the previous quarter. Product sales, net was the largest line at 87% of revenue.
Operating costs exceeded revenue by $44.1M, an operating margin of -2321.7%. The quarter ended with a net loss of $41.5M, wider than the previous quarter's $35.9M loss.
Operating cash flow was −$33.6M. Non-cash charges added back $111K of depreciation and amortization and $4.3M of share-based compensation. Working capital and other items added $3.5M. Capital expenditures of $18K exceeded it, leaving free cash flow of −$33.6M.
Questions
What was Lenz Therapeutics' revenue in the first quarter 2026?
Lenz Therapeutics (LENZ) reported revenue of $1.9M for the first quarter 2026 (Q1 2026) and +20% from the quarter before.
Source: Lenz Therapeutics 10-Q on SEC EDGAR.